CRISPR-Cas9 technology, while revolutionary in genetic engineering, presents significant experimental challenges.  Off-target effects, arising from the system's binding to unintended genomic sequences, remain a major hurdle.  Minimizing these requires careful guide RNA design and the employment of high-fidelity Cas9 variants, but complete elimination remains elusive, demanding rigorous validation techniques like whole-genome sequencing.  Furthermore, efficient delivery of the CRISPR-Cas9 system to target cells presents significant obstacles.  Viral vectors, while effective, can elicit immune responses, while non-viral methods often suffer from low transfection efficiency.  The complexity of delivering the system to specific tissues *in vivo*, particularly for therapeutic applications, poses further challenges.  Mosaicism, where only a subset of cells are successfully edited, further complicates therapeutic outcomes.  Finally, ethical considerations surrounding germline editing,  the potential for unforeseen consequences, and the accessibility of this powerful technology necessitate ongoing debate and robust regulatory frameworks.  Addressing these challenges is crucial for realizing CRISPR's full therapeutic and research potential.